PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 234 filers reported holding PDL BIOPHARMA INC in Q1 2014. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $4,000 | 0.0% | 1,688 | 0.0% | 0.00% | – |
| Q1 2020 | $4,000 | -94.0% | 1,688 | -92.6% | 0.00% | -100.0% |
| Q1 2018 | $67,000 | -76.2% | 22,800 | -77.8% | 0.00% | -66.7% |
| Q4 2017 | $281,000 | -31.5% | 102,600 | -15.2% | 0.00% | -40.0% |
| Q3 2017 | $410,000 | +477.5% | 121,000 | +315.8% | 0.01% | +400.0% |
| Q2 2017 | $71,000 | +31.5% | 29,100 | +20.7% | 0.00% | 0.0% |
| Q1 2017 | $54,000 | +74.2% | 24,100 | +60.7% | 0.00% | – |
| Q4 2016 | $31,000 | -95.4% | 15,000 | -92.5% | 0.00% | -100.0% |
| Q3 2016 | $674,000 | +5.0% | 201,300 | -1.6% | 0.01% | 0.0% |
| Q2 2016 | $642,000 | +1134.6% | 204,500 | +12000.6% | 0.01% | +900.0% |
| Q1 2016 | $52,000 | -11.9% | 1,690 | -31.1% | 0.00% | 0.0% |
| Q4 2015 | $59,000 | +637.5% | 2,454 | +611.3% | 0.00% | – |
| Q3 2015 | $8,000 | – | 345 | +34400.0% | 0.00% | – |
| Q4 2013 | $0 | -100.0% | 1 | -99.7% | 0.00% | – |
| Q3 2013 | $2,000 | -81.8% | 331 | -59.8% | 0.00% | – |
| Q2 2013 | $11,000 | – | 823 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |